Myeloid Clonal Infiltrate Identified With Next-Generation Sequencing in Skin Lesions Associated With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case Series

Grégoire Martin de Frémont, Pierre Hirsch, Santiago Gimenez de Mestral, Philippe Moguelet, Yoan Ditchi, Jean-François Emile, Patricia Senet, Sophie Georgin-Lavialle, Thomas Hanslik, François Maurier, Amir Adedjouma, Noémi Abisror, Thibault Mahervas, Florent Malard, Lionel Adès, Pierre Fenaux, Olivier Chasset, François Chassett, Arsène Mekinian and on behalf of MINHEMON (French Network of Dysimmune Disorders Associated With Hemopathies)

Background: Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are associated with cutaneous manifestations. Next-generation sequencing (NGS) is a tool capable of identifying clonal myeloid cells in the skin infiltrate and thus better characterize the link between hematological diseases and skin lesions.

Objective: To assess whether skin lesions of MDS/CMML are clonally related to blood or bone marrow cells using NGS.

Methods: Comparisons of blood or bone marrow and skin samples NGS findings from patients presenting with MDS/CMML and skin lesions in three French hospitals.

Results: Among the 14 patients recruited, 12 patients (86%) had mutations in the skin lesions biopsied, 12 patients (86%) had a globally similar mutational profile between blood/bone marrow and skin, and 10 patients (71%) had mutations with a high variant allele frequency (>10%) found in the myeloid skin infiltrate. Mutations in TET2 and
INTRODUCTION

Myelodysplastic syndromes (MDS) are defined as clonal hematopoietic disorders with ineffective hematopoiesis resulting in dysplasia, bone marrow failure, and peripheral cytopenias. Chronic myelomonocytic leukemia (CMML) is closely related to MDS and characterized by persistent monocytosis with medullar dysplastic features (1). During the last years, the diagnosis, prognosis staging, and therapeutical management of MDS/CMML have been modified by the emergence of next-generation sequencing (NGS), which allows the screening of mutations in multiple genes. Blood and/or bone marrow NGS allows to identify somatic mutations in more than 90% of patients suffering from MDS/CMML (2). In the setting of MDS/CMML, systemic inflammatory and autoimmune diseases (SIADs) occur in 10 to 30% patients, mostly neutrophilic diseases, connective tissue disorders, arthritis, and vasculitis (3–7). More than half of patients with SIADs have skin involvement, consisting in neutrophilic dermatosis and skin vasculitis, less frequently cutaneous granulomatosis (8–10). Other skin lesions including cutaneous infections, drug adverse reactions, and leukemia cutis (blastic myeloid cell infiltration of the skin) can be observed and must be distinguished from SIADs (11). Moreover, using fluorescent in situ hybridization (FISH) analyses, some studies suggested the skin infiltrate of neutrophilic dermatoses that arise in the context of myeloid malignancies have differentiated from the malignant clone (12). This has been shown particularly for histiocytoid Sweet’s syndrome (H-SS) (13). Similarly, a recent study using NGS demonstrated a clonal relationship between malignant cells of myeloid neoplasm and neutrophil infiltrate of Sweet’s syndrome (14). However, these findings were restricted to neutrophilic dermatoses and included a limited number of MDS/CMML patients. Interestingly, a case of NGS identifying a clonal infiltrate in myelodysplasia cutis, consisting in an immature myeloid histiocytoid non-blastic infiltrate in the setting of MDS, was recently reported, as defined by Osio et al. (15, 16). Given these preliminary data, we sought to better characterize skin lesions of patients with MDS/CMML using NGS, hypothesizing that a majority of skin lesions could be related to a clonal myeloid infiltrate of the skin and thus share common mutations with the hematological MDS/CMML clone found in blood and marrow.

**DNMT3A**, both in four patients, were the most frequent. Two patients harbored a **UBA1** mutation on hematopoietic samples.

**Limitations:** Limited number of patients and retrospective collection of the data. Blood and skin sampling were not performed at the exact same time point for two patients.

**Conclusion:** Skin lesions in the setting of MDS/CMML are characterized by a clonal myeloid infiltrate in most cases.

**Keywords:** myelodysplastic syndrome, chronic myelomonocytic leukemia, skin, next-generation sequencing, clonal hematopoiesis

PATIENTS AND METHODS

**Patients**

All consecutive patients with MDS or CMML referred to our department of internal medicine or dermatology in university tertiary centers between 2015 and 2020 for skin eruptions were enrolled in the study if a skin biopsy and NGS on at least one skin specimen were available. Skin lesions with a specific myelomonocytic infiltrate in pathology were referred as CMML cutis. Histiocytoid Sweet Syndrome (H-SS) was defined as a dermal infiltrate composed mostly of immature myeloid cells with histiocytic appearance as previously described (17). We decided to use the term *myelodysplasia cutis* only if lesions strictly corresponding to Osio et al.’s clinical and histological description were sampled (16). CMML/Erdheim Chester disease (ECD) was defined as a clonal cutaneous CMML infiltrate fulfilling ECD criteria (18). Of note, some biopsies did not have extensive immunohistochemical studies. *Leukemia cutis* was defined as a blastic infiltrate with CD34+, CD117+, or CD56+ cells. Skin biopsies of other patients addressed to our hospitals for *leukemia cutis* also underwent NGS to compare mutations and variant allele frequency (VAF) with those of non-blastic skin lesions. Three patients included in our case-series had previously been reported (18, 19).

**Molecular Analysis**

DNA was extracted from total bone marrow or blood samples using QIAsymphony (Qiagen) method, and from fresh or formalin-fixed paraffin-embedded (FFPE) tissue for skin samples (18). For a majority of samples, libraries were obtained from 112.5 ng of DNA using HaloPlex Target Enrichment System® (Agilent technologies), using a gene panel including main genes implied in myeloid malignancies as already described (20). For three samples (patients 9, 13, and 14) without enough DNA sample available for a second technique, other similar gene panels designed for myeloid malignancies diagnosis were used. Libraries were sequenced on a MiSeq® sequencer (IlluminaINC). Read alignment, variant calling, and annotation were performed using Sophia DDM® software version 5.0.12 (Sophia genetics). The sensitivity was 1%. All variants were checked using Integrative Genomics Viewer (IGV) software v2.3.

Sanger sequencing was performed for **UBA1** gene exon 3 for 12 patients with available hematopoietic samples (all patients but
8 and 12) and for one patient on skin sample (patient 8), as it was not included in the original gene panel.

**Ethics**

The study was conducted according to the French CNIL methodology reference and in accordance with the Declaration of Helsinki. Written informed consent was obtained from the patients unless dead at the time of the study.

**RESULTS**

**Patients’ Characteristics**

The patients are described in Tables 1, 2. The median age of the 14 patients was 70 years old at MDS/CMML diagnosis (ranging 62–81) and was 69 years old at the time of cutaneous manifestations (ranging 30–82). The MDS subtypes were MDS with multilineage dysplasia (n=3, including one with myelofibrosis), MDS with excess blasts (n=1), MDS with unilineage dysplasia (n=1), MDS/myeloproliferative neoplasm (MPN) (n=2), and CMML (n=7). Karyotype was normal in eight patients, abnormalities were found in five patients [del(20) (q11q13) in patient 5; iso(X)(p10) and (3;12)(p27.2;q24) in patient 6; trisomy 18 in patient 11; trisomy 8, del(1)(p34), (q11q13) in patient 5; iso(X)(p10) and t(3,12)(p21q24) in patients, abnormalities were found in.

**Cutaneous and Histological Features of MDS/CMML Patients**

Based on clinical, histological, and immunohistochemical findings and before NGS results, skin lesions have been classified as H-SS in four cases (patients 2, 7, 9, and 12), CMML cutis in three cases (patients 4, 6, and 11), and ECD associated with CMML cutis in two cases (patients 1 and 3) (18), Kikuchi-Fujimoto disease in one case (patient 5), neutrophilic folliculitis in one case (patient 10), erythema nodosum in one case (patient 13), pyoderma gangrenosum in one case (patient 14), and extensive livedo reticularis with non-specific findings on skin biopsy in one case (patient 8) (Tables 1, 2). Clinical and histological lesions are shown for patients 6, 7, and 14 (Figure 1).

**Comparison of Blood/Bone Marrow and Skin NGS Results**

Patients all had concomitant blood/marrow and skin sampling apart from patient 2 (skin biopsy performed 1 year before blood analysis with NGS) and patient 13 (skin biopsy performed 2 years before bone marrow analysis with NGS). At least one mutation was identified using NGS in blood/bone marrow in all

| TABLE 1 | Patients and skin lesion characteristics.  
|-----------|----------------|
| Patients’ characteristics (n = 14) |   |
| Male n (%) | 8 (57%) |
| Median age at MDS/CMML diagnosis, years old (range) | 70 (62–81) |
| Median age at skin lesions diagnosis, years old (range) | 69 (30–82) |
| Skin lesions preceding MDS/CMML n (%) | 5 (36%) |
| MDS subtypes: |   |
| MDS-MLD (%) | 3 (22%) |
| MDS-ULD (%) | 1 (7%) |
| MDS-EB (%) | 1 (7%) |
| MDS/MPN (%) | 2 (14%) |
| CMML (%) | 7 (50%) |
| Abnormal karyotype (%) | 5 (36%) |
| IPSS n (%): |   |
| Low risk | 7 (50%) |
| Intermediate-1 | 6 (43%) |
| Intermediate-2 | 1 (7%) |
| High | 0 |
| Extracutaneous manifestations n (%): |   |
| Fever (%) | 5 (36%) |
| Arthralgia or arthritis (%) | 6 (43%) |
| Skin lesion characteristics |   |
| Total number of biopsies | 14 |
| Diagnosis after clinic-pathological correlation: |   |
| H-SS | 4 |
| CMML cutis | 3 |
| Erdheim Chest disease/CMML cutis | 2 |
| Kikuchi-Fujimoto lupus | 1 |
| Neutrophilic folliculitis | 1 |
| Erythema nodosum | 1 |
| Pyoderma gangrenosum | 1 |
| Livedo reticularis with inclusive skin biopsy | 1 |

**Next-generation sequencing**

Positive NGS on hematopoietic samples 14 (100%)
Number of mutations, median (range) 2 (1–8)
Positive NGS on skin biopsies 12 (86%)
Percentage of myeloid cells, median (range) 20% (5–50%)
Number of mutations, median (range) 3.5 (1–7)
Diagnosis of skin clonal infiltrate following NGS 12 (86%)
Among positive NGS in skin biopsies:
Patients with at least one mutation in skin absent from blood/ BM 8 (67%)
Patients with at least one mutation in skin absent from blood/ BM 8 (67%)
Patients with at least one mutation in skin absent from blood/ BM 8 (67%)

**CMML:** chronic myelomonocytic leukemia; EB, excess blasts; ECD, Erdheim-Chester disease; IPSS, international prognostic scoring system; MDS, myelodysplastic syndromes; MLD, multi-lineage dysplasia; MPN, myeloproliferative neoplasm; NGS, next-generation sequencing; H-SS, Histiocytoid-Sweet’s syndrome; ULD, uni-lineage dysplasia; VAF, variant allele frequency.

patients with a median number of two mutations (ranging 1–8) and in skin biopsies in 12 patients with a median number of 3.5 mutations (ranging 1–7). Patient 5 was considered negative on skin owing to a very low skin VAF (<1%). Patient 8 was considered as a blood contamination as the weakly positive skin NGS (3% VAF) was not associated with a cutaneous myeloid infiltrate. Median VAF in skin was 12% (ranging from 1 to 76%) (Table 1). The same main mutation between blood/bone marrow and skin was found in eight patients (67% of patients with mutations in the skin). Six patients had paired
### Table 2 | Detailed patients' characteristics.

| ID | Age at first cutaneous lesions (years) | Age at hematological malignancy diagnosis (years) | Sex | Hematological malignancy | Cytogenetics | Skin lesions | Main clinical hypothesis/es before biopsy | Histology of skin biopsy | Immuno-histochemistry of skin biopsy | Diagnosis after clinic-pathological correlation | Skin clonal mutations (Yes/No) | VEXAS syndrome | Extracutaneous manifestations |
|----|--------------------------------------|-----------------------------------------------|-----|--------------------------|-------------|-------------|------------------------------------------|----------------------------|--------------------------------------|------------------------------------------|--------------------------|----------------|--------------------------------|
| 1  | 62                                   | 62                                           | F   | CMML                     |             | N           | Periodic and circumferential xanthomatosus lesions, Papulonodular lesions of the limbs and abdomen | Xanthelasma associated with histiocytes | Dense histiocytic infiltrate with plurinucleate cells and Touton cells | CD68+, CD163+, CD1a+ | ECD/CMLM cutis | Yes | No | No |
| 2  | 71                                   | 71                                           | M   | MDS-MLD and myelofibrosis |             | N           | Periodic and circumferential xanthomatosus lesions | Xanthelasma associated with histiocytes | Dense histiocytic infiltrate, partly immature | MPO+ | H-SS | Yes | Yes | Fever, asthenia, arthritis, paravertebral Atrophy, arthritis, pleuro-pericarditis, splenic infarct |
| 3  | 54                                   | 65                                           | F   | CMML                     |             | N           | Erythema-squamous papulonodular lesions of the limbs and back | Erythema-squamous papulonodular lesions | Dermal lymphohistiocytic infiltrate with plurinucleate cells | CD68+, CD163+, CD1a+ | ECD/CMLM cutis | Yes | No | No |
| 4  | 72                                   | 70                                           | M   | CMML                     | Del(20)(q11q13) | N           | Diffuse, painful, and sometimes erosive erythematous and violaceous papulonodular skin lesions of the extremities, thighs, arms, breasts, ears, and nose | Tumid lupus or SS or Kikuchi-Fujimoto lupus | Dermal inflammatory infiltrates with mainly regular mononuclear cells without dysplasia (lymphocytes, macrophages, plasmacytoid dendritic cells), nuclear debris or neutrophils associated with vacuolar alteration of basal keratinocytes, deep perivascular infiltrate of lymphocytes, and abundant mucin deposits in the reticular dermis | MPO+, CD163+, CD123+ | Kikuchi-Fujimoto lupus | No | No | No |
| 5  | 61                                   | 61                                           | F   | MDS-ULD                  | Del(20)(q11q13) | N           | Diffuse xanthomatous lesions | Dermal lymphohistiocytic infiltrate with plurinucleate cells | Dermal lymphohistiocytic infiltrate | CD68+, CD163+, CD1a+ | CMML cutis | Yes | No | No |
| 6  | 82                                   | 75                                           | F   | CMML                     | Iso(1)(p10), i(3;12)(p12;q24) | N           | Erythematous and pruritic papular lesions of the head, limbs, and trunk | OMML cutis or eczema | Dermal lymphoid and immature myeloid infiltrate | MPO+, CD68+, CD163+ | CMML cutis | Yes | No | No |
| 7  | 69                                   | 69                                           | F   | MDS-MLD                  | Too few mitoses to be performed | N           | Diffuse erythematous papular lesions | SS or leukemia cutis | Dermal lymphohistiocytic infiltrate | NA | H-SS | Yes | No | No |
| 8  | NA                                   | 70                                           | F   | MDS-EB2                  | Livedo      | N           | N               | Livedo associated with thrombophilia | NA | Inconclusive biopsy and no underlying thrombophilia | NA | Inconclusive biopsy and no underlying thrombophilia | No | No | No |
| 9  | 69                                   | 68                                           | M   | MDS-EB2/MPN              | N           | N           | Erythematous maculopapular lesions of the limbs and trunk | SS | Dermal lymphoid infiltrate with plurinucleate cells | CD163+ | H-SS | Yes | No | No |
| 10 | 82                                   | 81                                           | M   | MDS-ULD/MPN              | N           | N           | Folliculitis | Dermal lymphohistiocytic infiltrate with neutrophils | CD163+ | Neutrophilic folliculitis | Yes | No | Sjogren’s syndrome (sicca syndrome, arthritis) Adult Still disease (fever, asthenia, arthritis, pleuro-pericarditis) |
| 11 | 80                                   | 81                                           | M   | CMML                     | Trisomy 18  | N           | Erythematous papulonodular lesions | SS or Leukemia cutis | Dermal infiltrate of eosinophilic myelomonocytic cells | MPO+, CD68+, CD163, CD123, CD45, CD56+ | CMML cutis | Yes | No | No |
| 12 | 69                                   | 71                                           | M   | MDS-MLD                  | N           | N           | Papulonodular lesions | SS or infectious | Dermal histiocytic infiltrate with plurinucleate cells | CD34+, CD163+ | H-SS | Yes | Yes | Kikuchi-Fujimoto lupus (fever, asthenia, arthritis) |
| 13 | 77                                   | 77                                           | M   | CMML                     | Trisomy 8, del (1p11p34), del (5q13q13.3) | N           | Nodular lesions of the lower limbs | SS or erythema nodosum | Hypodermal lymphohistiocytic infiltrate with few plurinucleate cells with an aspect of septal panniculitis | NA | Erythema nodosum | Yes | NA | Fever, asthenia, arthritis, digestive vasculitis |
| 14 | 31                                   | 68                                           | M   | CMML                     | Del(1)(q223q28) | N           | Violaceous ulcerated and pustular lesions | Dense neutrophil infiltrate with histiocytes | Dermal histiocytic infiltrate with neoplastic cells | NA | Pyoderma gangrenosum | Yes | No | Yes |

CMML, chronic myelomonocytic leukemia; del, deletion; EB2, excess blasts subtype 2; ECD, Erdheim-Chester disease; F, female; iso, isochromosome; M, male; MDS, myelodysplastic syndromes; MLD, multilineage dysplasia; MPN, myeloproliferative neoplasm; MPO, myeloperoxidase; N, normal; NA, not available; (H)-SS, (Histiocytoid-)Sweet’s syndrome; t, translocation; ULD, unilineage dysplasia; ±, biopsyed skin lesions; s, skin biopsy analyzed with NGS; *, the 3% skin VAF with 0% myeloid infiltrate was interpreted as a blood contamination facilitated by a highly circulating clone (blood VAF 80%).
mutations in blood/marrow and skin lesions (patients 1, 2, 3, 4, 11, 12 with respectively ECD/CMML cutis, H-SS, ECCD/CMML cutis, CMML cutis, CMML cutis, and H-SS). For the six other patients, three had more mutations on blood/marrow than skin (patients 6, 10, and 14, with respectively CMML cutis, neutrophilic folliculitis, and pyoderma gangrenosum), and three had more mutations on skin than blood/marrow (patients 7, 9, and 13, with respectively H-SS, H-SS, and erythema nodosum). Patient 7 had one extra-mutation in skin (in TP53, VAF 2%), patient 9 had two extra-mutations in skin (in SETBP1, VAF 4%, and in KMT2D/MLL2, VAF 3%), and patient 13 had two extra-mutations in skin (in KRAS, VAF 11%, and in RUNX1, VAF 6%) and one extra-mutation in blood (in ZR5R2, VAF 7%) with a bone marrow analysis performed 2 years after skin sampling (Tables 2, 3). Regarding VAF, 10 patients had at least one mutation in skin with VAF >10% (patients 1, 3, 4, 6, 7, 9, 10, 11, 13, 14, with respectively ECD/CMML cutis, ECD/CMML cutis, CMML cutis, CMML cutis, H-SS, H-SS, neutrophilic folliculitis, CMML cutis, erythema nodosum, and pyoderma gangrenosum), of whom six had at least one mutation with VAF >20% (patients 4, 7, 10, 11, 13, 14, with respectively CMML cutis, H-SS, neutrophilic folliculitis, CMML cutis, erythema nodosum, and pyoderma gangrenosum), and two patients had detectable mutation with VAF <10% (patients 2 and 12 with 40 and 20% myeloid cells in the infiltrate, respectively, both diagnosed with H-SS). The myeloid infiltrate was of only 5% in three patients, but all of them had VAF >10% (patients 4, 7, and 9) (Tables 2, 3). The most frequent mutations were in DNMT3A and TET2 both found in four patients. Two patients harbored the recently identified mutations in UBA1 (2 and 12) (21), both having H-SS associated with a febrile polyarthitis.

Outcome and Treatment
Eleven patients have been treated and received oral steroids (n=8), hydroxychloroquine (n=2), immunosuppressive therapies (dapsone n=1), biological-targeted therapy (anakinra n=2, low-dose interleukin-2 n=1), or azacytidine as the hematological therapy (n=7). Azacytidine was associated with complete skin disease remission in three patients (two H-SS and one CMML cutis), partial in two (H-SS and pyoderma gangrenosum), and did not improve skin lesions in two (xanthelasma and folliculitis) (Table 4).

Two out of the 14 patients were dead by the end of data collection. One of them died of central nervous system infection (patient 11), and the other one of acute myeloid leukemia (patient 13).

Comparison to Patients With Leukemia Cutis
It is known that leukemia cutis is characterized by a skin infiltrate of blastic cells directly related to the myeloid leukemia. Therefore, NGS mutational profile of blood and skin lesions should be similar, and these patients could be used as “positive controls.” We aimed to compare the results of our MDS/CMML patients with patients having leukemia cutis focusing on the “VAF/percentage of myeloid cells in the skin infiltrate” ratio. Four patients referred for cutaneous lesions compatible with leukemia cutis had NGS on skin samples. Two had AML and two had CMML evolving to AML. Skin symptoms were prominent...
with nodular lesions diagnosed in three patients and erythroderma in one. *Leukemia cutis* NGS found a median number of mutations of 4 (versus 4.5 in blood or marrow for the same patients). The median VAF was 22% (ranging from 2 to 71%) in *leukemia cutis* (with a median percentage of myeloid cells in the infiltrate of >50%) compared with 12% (ranging from 1 to 76%) in the skin samples analyzed in our study (with a median percentage of myeloid cells in the infiltrate of 20%). The “VAF/percentage of myeloid cells in the skin infiltrate” ratio was similar between *leukemia cutis* and our skin samples (p=0.265

### TABLE 3 | Mutations in hematopoietic and skin samples.

| ID | Percentage of myeloid cells on the skin infiltrate | Gene(s) | Mutation | VAF hematopoietic sample (%) | VAF skin biopsy (%) |
|----|---------------------------------|---------|----------|-----------------------------|---------------------|
| 1  | 30%                             | NRAS    | NM_002524:c.38G>A:p.Gly13As | 41%                | 16%                |
| 2  | 40%                             | ZRSR2   | NM_005039:c.112dupA:p.Arg38Lysfs | 17%                | 2%                 |
| 3  | 40%                             | SFSB1   | NM_012433:c.2229A>G:p.Lys749Glu | 6%                 | 2%                 |
| 4  | 5%                              | UBA1†   | NM_153280.3:c.122T>C:p.Met41Thr | Yes                | NA                 |
| 5  | 10%                             | KRAS    | NM_004985:c.394G>C:p.Pro132Ala | 19%                | 21%                |
| 6  | 20%                             | ASXL1   | NM_015338:c.112dupA:p.Arg38Lysfs | 26%                | 14%                |
| 7  | 5%                              | TET2    | NM_01127208:c.822delC:p.Asp275Ilefs | 54%                | 14%                |
| 9  | 5%                              | CBL     | NM_005188:c.870-1G>A:p.? | 3% | Not detected |
| 10  |                               | EZH2    | NM_001127208:c.3384T>G:p.Tyr1128 | 4%          | Not detected |
| 11  | >50%                           | SMC1A   | NM_001127208:c.5676delT:p.His1893Thrfs | 48%                | 64%                |
| 12  | 20%                            | ASXL1   | NM_001127208:c.1154delC:p.Arg384fs | 4%          | Not detected |
| 13  | 20%                             | RIT1    | NM_001127208:c.1934dupC:p.Gly646Asp | 50%                | 38%                |
| 14  | >50%                          | DNMT3A  | NM_001127208:c.131dupC:p.Ala439fs | 5%                 | Not detected |
|     |                                | PP5M1D  | NM_001127208:c.117208:c.4035T>A:p.Tyr1345* | 11%               | 6%                 |

*Next-generation sequencing for all mutations shown apart from †UBA1 was sequenced with Sanger’s technique.*
TABLE 4 | Treatment outcome in skin lesions associated to MDS/CMML.

| ID   | Skin lesions                        | Mutations in the skin infiltrate | Systemic treatments received | Efficacy on skin lesions |
|------|-------------------------------------|----------------------------------|------------------------------|-------------------------|
| 1    | ECD/CMML cutis                      | NRAS                             | None                         | –                       |
| 2    | H-SS                                | NRAS, NRAS                        | Oral steroids                | None                    |
| 3    | ECD/CMML cutis                      | KRAS, ASXL1                       | Oral steroids, Hydroxychloroquine, Azacytidine | Partial (steroid dependence) |
| 4    | CMML cutis                          | TET2, DNMT3A                      | None                         | –                       |
| 5    | Kikuchi-Fujimoto lupus              | None                             | Oral steroids, Hydroxychloroquine, Azacytidine | Partial |
| 6    | CMML cutis                          | DNMT3A, RUNX1, SRSF2, TET2        | Oral steroids                | Total |
| 7    | H-SS                                | TP53, TP53, TP53                  | Azacytidine                 | Total |
| 8    | Inconclusive biopsy and no underlying thrombophilia | None                             | None                         | –                       |
| 9    | H-SS                                | SRSF2, EP300, CUX1, ASXL2, SETBP1, KMT2D/MLL2 | Azacytidine                 | Total |
| 10   | Neutrophilic folliculitis            | EZH2, ASXL1, IDH2, RUNX1          | Azacytidine, Low dose IL-2, Azacytidine | None |
| 11   | CMML cutis                          | SMC1A, ASXL1, EZH2, SETBP1        | Anakinra                     | Total |
| 12   | H-SS                                | TET2, DNMT3A                      | Anakinra                     | Partial |
| 13   | Erythema nodosum                    | ASXL1, RIT1, KRAS, RUNX1          | Oral steroids                | Total |
| 14   | Pyoderma gangrenosum                | TET2, DNMT3A, TP53, TET2, TET2, U2AF1 | Oral steroids, Dapsone, Azacytidine | Partial |

CMML, chronic myelomonocytic leukemia; ECD, Erdheim-Chester disease; H-SS, histiocytoid Sweet’s syndrome; IL, interleukin.

*Patients with VEXAS syndrome.

using Mann-Whitney test), supporting that mutations detected in skin biopsies of our MDS/CMML patients were related to a significant clonal myeloid infiltrate.

DISCUSSION

This case-series study highlights that despite heterogeneous clinical phenotypes of cutaneous lesions associated with MDS/CMML, a significant clonal skin infiltrate of MDS/CMML cells is found in most cases.

Recently, it has been shown using FISH in four patients and NGS in one patient followed for MDS that cutaneous lesions infiltrated by immature myeloid non-blastic cells were clonally related to the myeloid malignancy, and some authors suggested that they should be classified as *myelodysplasia cutis* (15, 16). Similarly, studying skin biopsies of patients with SS in the setting of MDS/CMML or acute myeloid leukemia, Passet et al. found a clonal infiltrate on the biopsies of 4/4 patients with a neutrophilic-SS associated with MDS/CMML (14). Our results confirmed these findings as all four patients diagnosed as H-SS before NGS had a clonal infiltrate related to the MDS and highlighted that other histiocytic or neutrophilic cutaneous disorders such as neutrophilic pustules, adult-xanthogranuloma, and pyoderma gangrenosum may also be characterized by a clonal infiltrate that shares a common clonal progenitor with MDS/CMML. Most patients had shared common mutations between paired blood/marrow and skin samples. Indeed, half of patients had identical paired mutations in blood/marrow and skin lesions, whereas some patients had additional mutations in skin or blood/bone marrows (n=3 each). This could be explained by a dissociated clonal evolution between hematopoietic tissue and skin once the original clone has spread to the skin.

Caution must, however, be exercised when interpreting VAF, which must be correlated to the percentage of myeloid cells infiltrating the skin to determine its significance and rule out a blood contamination, as in patient 8. Low VAF can be hard to interpret as in patient 5, considered negative but who also had a low circulating clonal burden, the low skin VAF thus did not strictly rule out a specific cutaneous localization of the myelodysplastic syndrome in this case.

The clinical diversity observed in our study is consistent with previous data in MDS/CMML-associated inflammatory manifestations. Despite efforts to classify these SIADs, they sometimes remain unlabeled. Apart from trisomy 8 associated with Behçet’s-like disease, no specific chromosomal abnormality has been associated with a particular clinical phenotype until now (7). Interestingly, an adult-onset autoinflammatory disease associated to *UBA1* somatic mutations was recently described in 25 patients, 24% showing MDS and 88% having skin involvement with lesions such as nodules and plaques (compatible with neutrophilic dermatosis or cutaneous vasculitis, peri orbital swelling, and severe cutaneous reaction to anakinra injection (21). In our study, we describe two new cases of VEXAS syndrome in patients with MDS associated to H-SS and extracutaneous symptoms. Furthermore, mutations in
TET2 and DNMT3A were the two most prevalent (four patients each) but are also among the most frequent mutations associated with MDS. On the contrary, mutations in SF3B1, found in approximately 20% patients with MDS, was only found in one patient with low cutaneous VAF in our study (22). Given the small number of patients and the clinical diversity, no mutation could be associated with a particular cutaneous phenotype, and whether some mutations are associated with particular skin lesions still needs to be clarified.

The demonstration of a common clonal progenitor between myeloid neoplasms and neutrophilic and H-SS (12, 14–16, 23) as well as clonal association between L-Group histiocytosis and MDS/CMML (18, 24) supports a role of blood cells in the development of extramedullary expression of MDS/CMML and enlightens the pathophysiology of these manifestations, what may guide treatment. Indeed, azacytidine seems to have a potential effect on MDS/CMML-associated SIADs in a retrospective study (25). In our series, hematological treatment proved at least partly efficient on skin lesions in five patients. NGS positivity did not seem associated with treatment response as the two non-responders had a cutaneous clonal infiltrate. Beyond extramedullary hematopoiesis, the upregulation of inflammatory pathways in the clonal cells could also explain the occurrence of skin lesions. Indeed, monocytes in CMML have highly pro-inflammatory features (26), and mutations commonly seen in MDS/CMML happen to be associated with higher inflammation (27). Interestingly, the case of a patient with CMML and CMML cutis was reported in an IL-10 pilot trial with marked improvement of skin lesions under treatment (28).

The dysregulation of pro-inflammatory pathways could explain the efficacy of immunosuppressive treatments in some patients. Our study has several limitations. First, we enrolled a limited number of patients due to the rarity of the condition studied and the enrollment in only three hospitals. Second, two patients did not have a concomitant blood/marrow and skin sampling, limiting the comparability of mutations in blood/marrow versus skin. Third, some data were collected retrospectively as patients were enrolled at the time skin lesions appeared. Fourth, concurrent treatment administration was frequent, limiting outcome interpretation. At last, our study design does not allow to assess the overall prevalence of cutaneous lesions among MDS/CMML patients and to assess differences between patients with or without cutaneous lesions in terms of molecular profile and prognosis.

Our data need further investigation including a genetic study of the other organs involved in SIADs associated with MDS/CMML and of the incidence of extramedullary clonal infiltration over survival.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article-supplementary material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

GF: conceptualization, data curation, formal analysis, methodology, and writing original draft. PH, SGM, FC, and AM: conceptualization, methodology, supervision, validation, and writing review and editing. Other authors: writing review and editing. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia. Blood (2016) 127(20):2391–405. doi: 10.1182/blood-2016-03-645344
2. Bacher U, Shumilov E, Flach J, Porret N, Joncourt R, Wiedemann G, et al. Challenges in the Introduction of Next-Generation Sequencing (NGS) for Diagnostics of Myeloid Malignancies Into Clinical Routine Use. Blood Cancer J (2018) 8(11):113. doi: 10.1182/s41408-018-0148-6
3. Braun T, Fenaux P. Myelodysplastic Syndromes (MDS) and Autoimmune Disorders (AD): Cause or Consequence? Best Pract Res Clin Haematol (2013) 26(4):327–36. doi: 10.1016/j.beha.2013.09.003
4. Castro M, Conn DL, Su WP, Garton JP. Rheumatic Manifestations in Myelodysplastic Syndromes. J Rheumatol (1991) 18(5):721–7.
5. Fain O, Braun T, Stirmann J, Fenaux P. Manifestations Systémiques Et Auto-Immunes Des Syndromes Myélodysplasiques. Rev Med Interne (2011) 32(9):552–9. doi: 10.1016/j.revmed.2010.08.005
6. Ustwani OA, Ford LA, Sait SJN, Block AMW, Barcos M, Vigil CE, et al. Myelodysplastic Syndromes and Autoimmune Diseases—Case Series and Review of Literature. Leuk Res (2013) 37(8):894–9. doi: 10.1016/j.leukres.2013.04.007
7. Wesner N, Drevon L, Guedon A, Fraison JB, Terrier B, Trad S, et al. Gastrointestinal Behçet’s-Like Disease With Myelodysplastic Neoplasms With Trisomy 8: A French Case Series and Literature Review. Leuk Lymphoma (2019) 60(7):1782–8. doi: 10.1080/10428194.2018.1542152
8. Yoneta K, Fujimoto N, Teramura K, Takayama S, Tanaka T. Disseminated Granulomatous Skin Lesions Associated With Myelodysplastic Syndrome Treated Successfully With Tranilast: A Case Report and Review of the Literature. Eur J Dermatol (2016) 26(4):398–400. doi: 10.1684/ejd.2016.2812
9. Balin SJ, Wetter DA, Kurtin PJ, Letendre L, Pittelkow MR. Myelodysplastic Syndrome Presenting as Generalized Granulomatous Dermatitis. Arch Dermatol (2011) 147(3):331. doi: 10.1001/archdermatol.2011.39
10. Farah C, Bulai Livideanu C, Jego J, Paul C, Viraben R, Lamant L, et al. Prevalence and Prognostic Value of Cutaneous Manifestations in Patients With Myelodysplastic Syndrome: Skin Manifestations and Myelodysplasia.
11. Mekinian A, Grignano E, Braun T, Decaux O, Liozon D, Cuccuini W, et al. Systemic Inflammatory and Autoimmune Manifestations Associated With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukaemia: A French Multicentre Retrospective Study. *Rheumatology* (2016) 55(2):291–300. doi: 10.1093/rheumatology/kew294

12. Sujobert P, Cuccuini W, Vignon-Pennamen D, Martin-García N, Albertini AF, Uznov M, et al. Evidence of Differentiation in Myeloid Malignancies Associated with Neutrophilic Dermatosis: A Fluorescent In Situ Hybridization Study of 14 Patients. *J Invest Dermatol* (2013) 133(4):1111–4. doi: 10.1038/jid.2012.408

13. Chavan RN, Cappel MA, Ketterling RP, Wada DA, Rochet NM, Knudson R, et al. Histiocytoid Sweet Syndrome: A Novel Application of Fluorescence In Situ Hybridization. *J Am Acad Dermatol* (2014) 70(6):1021–7. doi: 10.1016/j.jaad.2014.01.874

14. Passet M, Lepelletier C, Vignon-Pennamen M-D, Chasset F, Hirsch P, et al. Next-Generation Sequencing in Myeloid Neoplasms–Associated Sweet’s Syndrome Demonstrates Clonal Relation Between Malignant Cells and Skin-Infiltrating Neutrophils. *J Invest Dermatol* (2020) 140(9):1873–6.e5. doi: 10.1038/sj.jid.5533508

15. Delaleu J, Battistella M, Rathana K, Vignon-Pennamen M-D., Laurent C, Ram-Wolf C, et al. Identification of Clonal Skin Myeloid Cells by Next Generation Sequencing in Myelodysplasia Cutis. *Br J Dermatol* (2020) 184(2):367–9. doi: 10.1111/bjd.19547

16. Osio A, Battistella M, Feugeas J-P, Cuccuini W, Noguera M-E, Petrella T, et al. Myelodysplasia Cutis Versus Leukemia Cutis. *J Invest Dermatol* (2015) 135(9):2321–4. doi: 10.1038/jid.2015.146

17. Requena L, Kutzner H, Palmedo G, Pascual M, Fernández-Herrera J, Fraga J, et al. Histiocytoid Sweet Syndrome: A Dermal Infiltration of Immature Neutrophilic Granulocytes. *Arch Dermatol* (2005) 141(7):834–42. doi: 10.1001/archderm.141.7.834

18. Bonnet P, Chasset F, Moguëlet P, Abisror N, Itzykson R, Bouaziz J-D, et al. Erdheim-Chester Disease Associated With Chronic Myelomonocytic Leukemia Harboring the Same Clonal Mutation. *Haematologica* (2019) 104(11):e530–3. doi: 10.3324/haematol.2019.223552

19. Delplanque M, Chasset F, Hirsch P, Malard F, Ditchy I, Fain O, et al. Cutaneous Lupus With Kikuchi Disease-Like Inflammatory Pattern Associated With Myelodysplastic Syndrome. *Rheumatology* (2019) 58(3):554–6. doi: 10.1093/rheumatology/key413

20. Guermouche H, Ravale N, Gallay N, Deswarte C, Foucault A, Beaud J, et al. High Prevalence of Clonal Hematopoesis in the Blood and Bone Marrow of Healthy Volunteers. *Blood Adv* (2020) 4(15):3550–7. doi: 10.1182/bloodadvances.202001582

21. Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. *N Engl J Med* (2020) 383(27):2628–38. doi: 10.1056/NEJMoa2026834

22. Spaulding TP, Stockton SS, Savona MR. The Evolving Role of Next Generation Sequencing in Myelodysplastic Syndromes. *Br J Haematol* (2020) 188(2):224–39. doi: 10.1111/bjh.16212

23. Van Loon K, Gill RM, McMahon P, Chigurupati R, Siddiqi I, Fox L, et al. 20q– Clonality in a Case of Oral Sweet Syndrome and Myelodysplasia. *Am J Clin Pathol* (2012) 137(2):310–5. doi: 10.1309/AJCPI7RWLYTJHV

24. Papo M, Diamond EL, Cohen-Aubart F, Emile J-F, Roos-Weil D, Gupta N, et al. High Prevalence of Myeloid Neoplasms in Adults With Non–Langerhans Cell Histiocytosis. *Blood* (2017) 130(8):1007–13. doi: 10.1182/blood-2017-07-761718

25. Fraison J-B, Mekinian A, Grignano E, Kahn J-E, Arlet J-B, Decaux O, et al. Efficacy of Azacitidine in Autoimmune and Inflammatory Disorders Associated With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. *Leuk Res* (2016) 43:13–7. doi: 10.1016/j.leukres.2016.02.005

26. Franzini A, Pomicter AD, Yan D, Khorashad JS, Tantravahi SK, Than H, et al. The Transcriptome of CML Monocytes Is Highly Inflammatory and Reflects Leukemia-Specific and Age-Related Alterations. *Blood Adv* (2019) 3(20):2949–61. doi: 10.1182/bloodadvances.2019000585

27. Cull AH, Snetsinger B, Buckstein R, Wells RA, Rauh MJ. Tet2 Restrains Inflammatory Gene Expression in Macrophages. *Exp Hematol* (2017) 55:56–70.e13. doi: 10.1016/j.exphem.2017.08.001

28. Pöchlauer S, Jäger E, Jäger U, Geissler K. Recombinant Human Interleukin-10 Inhibits Differentiation of Immature Dendritic Cells and Reduces Inflammatory and Autoimmune Gene Expression in Macrophages. *Exp Hematol* (2019) 75:61–73. doi: 10.1016/j.exphem.2019.02.011

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Martin de Frémont, Hirsch, Gimenez de Mestral, Moguëlet, Ditchi, Emile, Senet, Georgin-Lavaille, Hafsik, Maurier, Aderjouma, Abisror, Mahevas, Malard, Adès, Fenaux, Fain, Chasset and Mekinian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.